论文部分内容阅读
对房颤病人常用传统IA类抗心律失常药物(奎尼丁、普鲁卡因胺和丙吡胺)预防复发或减少阵发次数和持续时间,但这类药物对维持窦性心律往往无效或伴有副作用,因而临床上需要使用较新的药物,本文随机比较研究普罗帕酮和索他洛尔对传统治疗无效病人,防止复发性症状性房颤的效果和安全性。对象为房颤或房扑病人,具有使用≥1种上述IA类药物,且有≥1次治疗无效的病史。并分为4个亚组:①慢性房颤和左房大(前后径≥4.5cm);②慢性房颤和左房不大(<4.5cm);③阵发性房颤和左房大;④阵发性房颤和左房不大。对慢性房颤转律(药
Traditional Class IA antiarrhythmic drugs (quinidine, procainamide, and disopyramide) commonly used in patients with atrial fibrillation prevent recurrence or reduce the frequency and duration of episodes, but these drugs are often ineffective in maintaining sinus rhythm Accompanied by side effects, and therefore need to use more clinically new drugs, this randomized comparative study of propafenone and sotalol in patients with traditional treatment ineffective, to prevent the recurrence of symptomatic atrial fibrillation effect and safety. Subjects with atrial fibrillation or atrial flutter have a history of using ≥1 IA drugs listed above and having ≥1 treatment discontinuation. And divided into four subgroups: ① chronic atrial fibrillation and left atrium (anteroposterior diameter ≥ 4.5cm); ② chronic atrial fibrillation and left atrium is not (<4.5cm); ③ paroxysmal atrial fibrillation and left atrium large; ④ paroxysmal atrial fibrillation and left atrial not. Chronic atrial fibrillation (drug